Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilrekimig plus background standard care versus placebo in moderate-to-severe atopic dermatitis
jRCT2031260599Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Tilrekimig arm with Placebo arm (2 arms). Primary endpoints: EASI75 responders at Week 16 and vIGA-AD 0/1 responders at Week 16. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
tilrekimig
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031260599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260599.